Surgical management of thymic epithelial tumors: A retrospective review of 204 cases

被引:46
作者
Fang, WT
Chen, WH
Chen, G
Jiang, Y
机构
[1] Shanghai Chest Hosp, Dept Thorac Surg, Shanghai 200030, Peoples R China
[2] Shanghai Chest Hosp, Dept Pathol, Shanghai 200030, Peoples R China
关键词
D O I
10.1016/j.athoracsur.2005.05.058
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background. Thymic epithelial tumors consist of a series of neoplasm that differ morphologically and biologically. Management strategy for these tumors remains controversial. Methods. We retrospectively reviewed 204 thymic epithelial tumors surgically treated during the period of 1970 to 1995, and we reexamined the histologic specimens using the current World Health Organization classification. Results. One hundred eighty patients (88.2%) underwent complete resections, 17 (8.3%) received partial resections, and 7 (3.4%) received biopsies only. The complete resection rate of stages I and II tumors was significantly higher than stages III and IV tumors (98.2% vs 76.6%; p < 0.001). Twenty-four patients (11.8%) experienced 29 events of complications postoperatively, including 11 events of myasthenia gravis crisis. Myasthenia gravis, partial resection or biopsy, and stages III and IV were independent risk factors for postoperative complications. Fifteen patients (7.4%) died during hospital stays, including 6 patients from myasthenia crisis. Partial resection or biopsy and myasthenia gravis were independent risk factors for postoperative mortality. There were significantly more stage I and stage II cases in histologic types A, AB, and B1 tumors than in B2, B3, and C tumors (87.6% vs 26.4%; p < 0.001), and their complete resection rate was significantly higher than the latter group (98.9% vs 78.3%; p < 0.001). The 5-year and 10-year survival rates were 63.2% and 50.4%, respectively. Masaoka stages III and IV, histologic types B2, B3, and C, and incomplete resection were independent risk factors for poor prognosis. Conclusions. Complete resection remains the hope of cure for thymic epithelial tumors. The treatment strategy should be based on the current World Health Organization histologic classification and the Masaoka staging system.
引用
收藏
页码:2002 / 2007
页数:6
相关论文
共 25 条
  • [1] Primary chemotherapy with adriamycin, cisplatin, vincristine and cyclophosphamide in locally advanced thymomas: a single institution experience
    Berruti, A
    Borasio, P
    Gerbino, A
    Gorzegno, G
    Moschini, T
    Tampellini, M
    Ardissone, F
    Brizzi, MP
    Dolcetti, A
    Dogliotti, L
    [J]. BRITISH JOURNAL OF CANCER, 1999, 81 (05) : 841 - 845
  • [2] New WHO histologic classification predicts prognosis of thymic epithelial tumors - A clinicopathologic study of 200 thymoma cases from China
    Chen, G
    Marx, A
    Chen, WH
    Yong, J
    Puppe, B
    Stroebel, P
    Mueller-Hermelink, HK
    [J]. CANCER, 2002, 95 (02) : 420 - 429
  • [3] Experience with programmed steroid treatment with thymectomy in nonthymomatous myasthenia gravis
    Endo, S
    Yamaguchi, T
    Saito, N
    Otani, S
    Hasegawa, T
    Sato, Y
    Sohara, Y
    [J]. ANNALS OF THORACIC SURGERY, 2004, 77 (05) : 1745 - 1750
  • [4] Surgical management of thymic epithelial tumors: A retrospective review of 204 cases
    Fang, WT
    Chen, WH
    Chen, G
    Jiang, Y
    [J]. ANNALS OF THORACIC SURGERY, 2005, 80 (06) : 2002 - 2007
  • [5] Harris NL, 1999, AM J CLIN PATHOL, V112, P299
  • [6] WHO histologic classification is a prognostic indicator in thymoma
    Kondo, K
    Yoshizawa, K
    Tsuyuguchi, M
    Kimura, S
    Sumitomo, M
    Morita, J
    Miyoshi, T
    Sakiyama, S
    Mukai, K
    Monden, Y
    [J]. ANNALS OF THORACIC SURGERY, 2004, 77 (04) : 1183 - 1188
  • [7] Kornstein MJ, 1999, AM J CLIN PATHOL, V112, P304
  • [8] CISPLATIN PLUS DOXORUBICIN PLUS CYCLOPHOSPHAMIDE IN METASTATIC OR RECURRENT THYMOMA - FINAL RESULTS OF AN INTERGROUP TRIAL
    LOEHRER, PJ
    KIM, K
    AISNER, SC
    LIVINGSTON, R
    EINHORN, LH
    JOHNSON, D
    BLUM, R
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (06) : 1164 - 1168
  • [9] Cisplatin, doxorubicin, and cyclophosphamide plus thoracic radiation therapy for limited-stage unresectable thymoma: An intergroup trial
    Loehrer, PJ
    Chen, M
    Kim, KM
    Aisner, SC
    Einhorn, LH
    Livingston, R
    Johnson, D
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (09) : 3093 - 3099
  • [10] THYMOMA - RESULTS OF 241 OPERATED CASES
    MAGGI, G
    CASADIO, C
    CAVALLO, A
    CIANCI, R
    MOLINATTI, M
    RUFFINI, E
    [J]. ANNALS OF THORACIC SURGERY, 1991, 51 (01) : 152 - 156